A controversial Alzheimer’s drug has already yielded $2 million in sales.. Aduhelm (Drug), Alzheimer's Disease, Medicare, Biogen Inc, Food and Drug Administration, Drugs (Pharmaceuticals), Health Insurance and Managed Care, Vounatsos, Michel